Cash as of 30 September 2018 was $1542K. After receiving R&D Tax Incentive refund of 3.1 million. Cash as of 31 Oct 2018 was $3.5 million. Expected cash as of 31 December 2018 will be $1.4 million. It will be very interesting to see December quarterly cashflow report next week. Also how we go with the issue of convertible notes.
Next March quarter 4C cash outfloiw and expected FDA 510K clearance in next 3 months is the key to assess new leadership and management.
MEB Price at posting:
2.0¢ Sentiment: Buy Disclosure: Held
